{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:43:42Z","timestamp":1783665822583,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.eururo.2005.04.011","type":"journal-article","created":{"date-parts":[[2005,5,12]],"date-time":"2005-05-12T07:45:15Z","timestamp":1115883915000},"page":"656-661","source":"Crossref","is-referenced-by-count":58,"title":["Liposomal Recombinant Human Superoxide Dismutase for the Treatment of Peyronie's Disease: A Randomized Placebo-Controlled Double-Blind Prospective Clinical Study"],"prefix":"10.1016","volume":"48","author":[{"given":"Claus R.","family":"Riedl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sternig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Gall\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Langmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta","family":"Vcelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karola","family":"Vorauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Katinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Pfl\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2005.04.011_bib1","series-title":"Campell's Urology","first-page":"1696","article-title":"Peyronie's Disease","author":"Lewis","year":"2002"},{"key":"10.1016\/j.eururo.2005.04.011_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","article-title":"Proposal: trauma as the cause of the Peyronie's lesion","volume":"157","author":"Devine","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib3","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0022-5347(17)39746-X","article-title":"The natural history of Peyronie's disease","volume":"144","author":"Gelbard","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1464-410X.2004.04945.x","article-title":"Are the current conservative treatments for Peyronie's Disease evidence-Based?","volume":"94","author":"Gontero","year":"2004","journal-title":"Br J Urol Int"},{"key":"10.1016\/j.eururo.2005.04.011_bib5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0022-5347(05)64691-5","article-title":"Experience with intraplaque injection of verapamil for Peyronie's disease","volume":"168","author":"Levine","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","article-title":"Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study","volume":"149","author":"Gelbard","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-5347(05)67981-5","article-title":"Iontophoresis for the treatment of Peyronie's disease","volume":"163","author":"Riedl","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/j.1939-4640.2000.tb03279.x","article-title":"Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results","volume":"21","author":"Montorsi","year":"2000","journal-title":"J Androl"},{"key":"10.1016\/j.eururo.2005.04.011_bib9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ju.0000116450.82816.2c","article-title":"A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease","volume":"171","author":"Di Stasi","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-2008-1061403","article-title":"Die Behandlung der Peyronie's Disease mit SOD-Injektion. Attraktive Alternative zu den bisherigen Therapieverfahren?","volume":"6","author":"DeVries","year":"1988","journal-title":"Akt Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib11","first-page":"250","article-title":"Orgotein, a new drug for the treatment of Peyronie's disease","volume":"4","author":"Bartsch","year":"1981","journal-title":"Eur J Rheumatol Inflamm"},{"key":"10.1016\/j.eururo.2005.04.011_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000473262","article-title":"Peyronie's disease: experience of local treatment with orgotein","volume":"7","author":"Gustafson","year":"1981","journal-title":"Eur J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib13","first-page":"169","article-title":"Orgotein in the treatment of plastic induration of the penis (Peyronie's disease)","volume":"25","author":"Primus","year":"1993","journal-title":"Int Urol Nephr"},{"key":"10.1016\/j.eururo.2005.04.011_bib14","first-page":"103A","article-title":"Orgotein versus hydrocortisone in the treatment of Peyronie's disease. A randomized study","volume":"135","author":"Berlin","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib15","first-page":"24","article-title":"Humane rekombinante Superoxiddismutase","volume":"6","author":"Bayer","year":"1990","journal-title":"Bioengineering"},{"key":"10.1016\/j.eururo.2005.04.011_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0021-9673(92)87218-W","article-title":"Scale-up of recombinant protein purification by hydrophobic interaction chromatography","volume":"625","author":"Vorauer","year":"1992","journal-title":"J Chromatography"},{"key":"10.1016\/j.eururo.2005.04.011_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0939-6411(02)00045-0","article-title":"Long term stability of rh-Cu\/Zn-superoxide dismutase (SOD)-liposomes prepared by the cross-flow injection technique following International Conference on Harmonisation (ICH)-guidelines","volume":"54","author":"Vorauer-Uhl","year":"2002","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.eururo.2005.04.011_bib18","unstructured":"Schriebl K, Wagner A, F\u00fcrnschlief E, Katinger H, Vorauer-Uhl K. Aspects and limitations of in-vivo penetration studies of liposomal formulations\u2014case study of liposomal human Cu\/Zn-superoxide dismutase. Submitted to Int J Pharm, 2005."},{"key":"10.1016\/j.eururo.2005.04.011_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0939-6411(02)00062-0","article-title":"Liposomes produced in a pilot scale: production, purification and efficiency aspects","volume":"54","author":"Wagner","year":"2002","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.eururo.2005.04.011_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000049797","article-title":"Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease","volume":"40","author":"Riedl","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"Schnitker K, and the Peyronie's Disease Study Group of the Andrological Group of the German Urologists. Potassium paraaminobenzoate (Potaba\u2122) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study","volume":"47","author":"Weidner","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib22","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.ju.0000053800.62741.fe","article-title":"Peyronie's disease: a review","volume":"169","author":"Gholami","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","article-title":"A retrospective review of 307 men with Peyronie's disease","volume":"168","author":"Kadioglu","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/niox.2001.0421","article-title":"Antifibrotic role of inducible nitric oxide synthase","volume":"6","author":"Ferrini","year":"2002","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.eururo.2005.04.011_bib25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","article-title":"The treatment of Peyronie's disease with tamoxifen","volume":"70","author":"Ralph","year":"1992","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1124\/jpet.103.064154","article-title":"A newly identified role for superoxide in inflammatory pain","volume":"309","author":"Wang","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.eururo.2005.04.011_bib27","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1152\/ajpcell.2001.280.4.C719","article-title":"Oxidant stress and endothelial cell dysfunction","volume":"280","author":"Lum","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.eururo.2005.04.011_bib28","first-page":"387","article-title":"New insights into the etiological pathogenesis of Peyronie's disease","volume":"34","author":"Hauck","year":"2003","journal-title":"Akt Urol"},{"key":"10.1016\/j.eururo.2005.04.011_bib29","first-page":"4S","article-title":"Randomized prospective placebo-controlled therapy of Peyronie's disease (IPP) with Potaba (aminobenzoate potassium)","volume":"161","author":"Weidner","year":"1999","journal-title":"J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283805002563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283805002563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T17:04:30Z","timestamp":1706202270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283805002563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0302283805002563"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2005.04.011","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}